Scotland: Hope for patients with pulmonary fibrosis

scotland

The Scottish Medicines Consortium (SMC) has announced that the anti-fibrotic medicine nintedanib has been accepted for use by NHS Scotland for the treatment of patients with the lung scarring disease pulmonary fibrosis.  Action for Pulmonary Fibrosis (APF) has spearheaded a campaign for patients in Scotland with the support of patients, families and medical experts, to […]

Read More… from Scotland: Hope for patients with pulmonary fibrosis

Victory for thousands of terminally ill patients

patients

Antifibrotic drugs offer hope to thousands of patients who are living with a condition that has a worse outcome than most cancers. · Action for Pulmonary Fibrosis (APF) is delighted to announce their campaign, backed by patients, families and medical experts, to end the inhumane restrictions on life-extending antifibrotic drugs has been successful. · Today […]

Read More… from Victory for thousands of terminally ill patients